Origami Therapeutics, Inc.
Origami Therapeutics, Inc., based in San Diego, CA, is a healthcare company specializing in therapeutics for neurodegenerative diseases using machine learning and computational chemistry. The company is known for its proprietary drug discovery platform, ORICISION™, and is part of the Y Combinator W22 batch.
Company Overview
Origami Therapeutics, Inc., located in San Diego, CA, USA, focuses on healthcare, specifically within the therapeutics sub-industry. The company, consisting of a small team of 4, has garnered attention for its innovative solutions aimed at treating neurodegenerative diseases. As a member of the Y Combinator W22 batch, Origami Therapeutics has made significant strides in developing next-generation disease-modifying therapies.
Innovative Drug Discovery Platform: ORICISION™
Origami Therapeutics leverages its proprietary drug discovery platform, ORICISION™, to develop treatments for neurodegenerative diseases. Utilizing machine learning and computational chemistry, the company targets and degrades disease-related proteins. This approach is anticipated to be broadly applicable to traditionally 'undruggable' targets in various neurological diseases.
Focus on Huntington’s Disease
Origami Therapeutics is initially focusing on Huntington’s disease, developing oral drugs designed to halt the progression of this neurodegenerative condition. The company has identified small molecules that reduce the toxic mutated protein, suppressing mutant protein-induced toxicities in human disease neurons. This strategy aims to delay or halt disease progression effectively.
Participation in Industry Conferences and Media Features
Origami Therapeutics has been actively involved in numerous industry conferences and showcases, including the 17th Annual Huntington’s Disease Therapeutics Conference and the 10th Annual Neurodegenerative Drug Development Summit. The company also participated in the Demy Colton BioFuture Conference and the RESI Digital: Investing in Precision Medicine panel. Additionally, it was featured in media outlets like MedCity News and BioCentury for its cutting-edge approach.
Leadership in Neurodegenerative Disease Roles
Beth Hoffman, CEO of Origami Therapeutics, is a notable figure in the field of neurodegenerative diseases. She is a member of the Huntington’s Disease Society of America (HDSA) National Board of Trustees. Under her leadership, the company was listed as one of BioCentury’s 2021 Class of Emerging Companies, highlighting its potential and innovative contributions to the industry.